You are now leaving the Hypermunes.com Web site.

Links to external, non-Grfols Therapeutics Inc. Internet sites are provided as a courtesy; however, Grifol Therapeutics Inc. is not responsible for the availability or the content of such Web sites.

Please see our General Conditions of Use for more information.

OK     CANCEL
 

HyperRAB® S/D [Rabies Immune Globulin (Human)]
postexposure prophylaxis for rabies

HyperRAB® S/D Postexposure Prophylaxis for Rabies

Up to 39,000 persons come in contact with potentially rabid animals and receive rabies postexposure prophylaxis each year.1,2

According to the Centers for Disease Control and Prevention (CDC), rabies is almost always fatal, but is almost 100% preventable with the comprehensive treatment that can only be provided with a rabies immune globulin, such as HyperRAB S/D in conjunction with a vaccine, such as RabAvert® (rabies vaccine).3,4

For more information, recommendations, and guidelines, visit the CDC—Advisory Committee on Immunization Practices (ACIP).

Hypermunes Vaccine Visual Aid https://www.novartisvaccinesdirect.com/Rabavert/RabavertAbout

Imminent Threat

Vaccines can take weeks to build efficacy. HyperRAB S/D provides immediate protection. This allows the vaccine the time needed to establish active immunity, giving your patients the critical protection they need now.5

Immediate Protection

HyperRAB S/D contains high titers of rabies antibodies for postexposure prophylaxis, providing rapid immune protection. When used in combination with a vaccine, such as RabAvert, along with the appropriate wound cleansing, a rabies immune globulin such as HyperRAB S/D is recommended by the CDC and WHO.1,6,7*

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.


HyperRAB S/D IMPORTANT SAFETY INFORMATION


Rabies vaccine and HyperRAB S/D should be given to all persons suspected of exposure to rabies with one exception: persons who have been previously immunized with rabies vaccine and have a confirmed adequate rabies antibody titer should receive only vaccine.

HyperRAB S/D (Rabies Immune Globulin [Human]) should be given with caution to patients with a history of prior systemic allergic reactions following the administration of human immunoglobulin preparations.

The attending physician who wishes to administer HyperRAB S/D to persons with isolated immunoglobulin A (IgA) deficiency must weigh the benefits of immunization against the potential risks of hypersensitivity reactions. Such persons have increased potential for developing antibodies to IgA and could have anaphylactic reactions to subsequent administration of blood products that contain IgA.

As with all preparations administered by the intramuscular route, bleeding complications may be encountered in patients with thrombocytopenia or other bleeding disorders.

Soreness at the site of injection and mild temperature elevations may be observed at times. Sensitization to repeated injections has occurred occasionally in immunoglobulin-deficient patients. Angioneurotic edema, skin rash, nephrotic syndrome, and anaphylactic shock have rarely been reported after intramuscular injection so that a causal relationship between immunoglobulin and these reactions is not clear.

Administration of live virus vaccines (e.g., MMR) should be deferred for approximately 3 months after rabies immune globulin (human) administration.

HyperRAB S/D is made from human plasma. Product made from human plasma may contain infectious agents, such as viruses, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent that can cause disease. There is also the possibility that unknown infectious agents may be present in such products.

For full Prescribing Information, click here.

RabAvert IMPORTANT SAFETY INFORMATION

RabAvert (rabies vaccine) is indicated for preexposure vaccination, in both primary series and booster dose, and for postexposure prophylaxis against rabies in all age groups.

Anaphylaxis, encephalitis including death, meningitis, neuroparalytic events such as encephalitis, transient paralysis, Guillain-Barré Syndrome, myelitis, and retrobulbar neuritis; and multiple sclerosis have been reported to be temporally associated with the use of RabAvert.

The most commonly occurring adverse reactions are injection site reactions, such as injection site erythema, induration and pain; flu-like symptoms; arthralgia; dizziness; lymphadenopathy; nausea; and rash.

History of anaphylaxis to the vaccine or any of the vaccine components constitutes a contraindication to preexposure vaccination with this vaccine. In the case of postexposure prophylaxis, if an alternative product is not available, vaccination should proceed with caution and close observation. A patient’s risk of acquiring rabies must be carefully considered before discontinuing vaccination.

For full Prescribing Information, click here.

*World Health Organization.

References:

  1. Manning SE, Rupprecht CE, Fishbein D, et al; Centers for Disease Control and Prevention. Human rabies prevention—US, 2008: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 2008;57(RR03):1-38.

  2. Krebs JW, Long-Marin SC, Childs JE. Causes, costs, and estimates of rabies postexposure prophylaxis treatments in the United States. J Public Health Manage Pract. 1998;4:56-62.

  3. Centers for Disease Control and Prevention. CDC Features. Global efforts to control and prevent rabies. http://www.cdc.gov/Features/Rabies. Accessed June 15, 2009.

  4. Centers for Disease Control and Prevention. Health Marketing. http://www.cdc.gov/healthmarketing/entertainment_education/tips/batbite.htm. Accessed June 15, 2009.

  5. Baxter D. Active and passive immunity, vaccine types, excipients and licensing. Occupational Medicine. 2007;57:552-556.

  6. Centers for Disease Control and Prevention. Human rabies prevention—US, 1999: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR. 1999;48(RR-1):1-21.

  7. World Health Organization. Current WHO guide for rabies pre and post-exposure prophylaxis in humans. http://www.who.int/rabies/en/WHO_guide_rabies_pre_post_exp_treat_humans.pdf. Accessed April 16, 2009.

RabAvert is a registered trademark of Novartis Vaccines and Diagnostics Inc.